[6-K] Agomab Therapeutics NV Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Analyzing...

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-07291

AgomAb Therapeutics NV

Posthoflei 1/6 2600

Antwerpen, Belgium

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

EXHIBIT INDEX

Exhibit No		Description
3.1		Amended and Restated Articles of Association

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AgomAb Therapeutics NV
By:	/s/ Tim Knotnerus
	Tim Knotnerus
	Chief Executive Officer

Date: March 5, 2026

Filing Exhibits & Attachments

1 document

Other Documents

• EX-3.1 EXHIBIT 3.1 118.0 KB